Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07764588

Innate Immune Cell Phenotypes and Early Fibrotic Repair in Acute Myocardial Infarction

To determine the relationship of the phenotypes of neutrophils and monocytes with early fibrotic repair after acute myocardial infarction.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Myocardial Infarction Cardiovascular Diseases Heart Diseases Infarction Ischemia Myocardial Ischemia Necrosis Pathologic Processes Pathological Conditions, Signs and Symptoms Vascular Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Shanghai Tenth People's Hospital

Shanghai, China

Location status: Recruiting

Location contact

Ethics Committee of Shanghai Tenth People's Hospital

CONTACT

[email protected]

86-21-66301604

About this study

This study will enroll 50 patients with ST-segment elevation myocardial infarction (STEMI). Peripheral blood will be collected from these patients for immune cell subset analysis, serum cytokine evaluation, and neutrophil sorting for transcriptome sequencing. At 1 week after admission, cardiac magnetic resonance (CMR) will be performed to evaluate the myocardial salvage index, area of late gadolinium enhancement (LGE), microvascular obstruction (MVO), extracellular volume (ECV), and left ventricular ejection fraction (LVEF).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

---- Age > 18 and ≤ 80 years old

  • Patients with acute STEMI within 12 hours of symptom onset who are planned to receive PPCI

Exclusion criteria

  • Prior revascularization
  • Known allergy to gadopentetate dimeglumine contrast agent
  • Pregnancy or planned pregnancy within the next 6 months
  • Life expectancy < 1 year
  • Metallic implants or claustrophobia that precluded MRI
  • Severe COPD or inability to hold breath for MRI
  • Severe hepatic or renal dysfunction (ALT > 5×ULN or eGFR < 15 mL/min/1.73 m²)

Treatment and study plan

Primary outcomes

  1. Major cardiac adverse outcome

    Time frame: At 12 months after enrollment

    The composite endpoint included cardiac death, non-fatal myocardial infarction, and rehospitalization for angina.

Secondary outcomes

  1. Cardiac remodeling measured by CMR

    Time frame: At 1 week after admission

    CMR will be performed to evaluate the cardiac fibrosis defined as area of late gadolinium enhancement (LGE).

Study contacts

Contact information is provided by the study sponsor or research team.

Jianhui Zhuang, MD

CONTACT

[email protected]

86-13621742833

Sponsors and collaborators

Lead sponsor

Shanghai 10th People's Hospital

Other

Registry information

Acronym: ICE-AMI

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Aug 14, 2026
Registry last updated
Aug 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.